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PPNDSNorovirus (NV) is a major cause of gastroenteritis worldwide. Antivirals against such important
pathogens are on demand. Among the viral proteins that orchestrate viral replication, RNA-depen-
dent-RNA-polymerase (RdRp) is a promising drug development target. From an in silico-docking
search focused on the RdRp active site, we selected the compound PPNDS, which showed low
micromolar IC50 vs. murine NV-RdRp in vitro. We report the crystal structure of the murine NV-
RdRp/PPNDS complex showing that two molecules of the inhibitor bind in antiparallel stacking
interaction, properly oriented to block exit of the newly synthesized RNA. Such inhibitor-binding
mode mimics two stacked nucleotide-bases of the RdRp/ssRNA complex.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction mNV is closely related to human NV (hNV), but contrary to hNV,The Caliciviridae family includes human and non-human
pathogens, clustering so far in four accepted genera: Norovirus
(NV), Sapovirus (SV), Lagovirus and Vesivirus [1–4]. Such viruses
cause a broad spectrum of diseases, which may range from acute
gastroenteritis in humans (NV and SV) to hemorrhagic disease in
rabbits (rabbit hemorrhagic disease virus) and upper airway
infection in cats (feline calicivirus) to lethal encephalitis in
immune-deﬁcient mice (caused by murine Norovirus, mNV) [5,6].
Currently no vaccines or speciﬁc antiviral agents are available to
combat these pathogens, with the exception of a vaccine for feline
NV [7]. Thus there is an urgent need for the discovery of broad-
spectrum therapeutics for treating their related infections [8].it grows in culture and in a small animal model, thus providing a
tractable model to study NV biology [9]. There are at least six NV
genotypes, parts of which comprise subgenotypes; mNV belongs
to genotype V. Thus, should an inhibitor prove active against
mNV in cell cultures, it would likely be active also against hNV of
various genotypes.
The NV genome, composed of 7.3–8.5 kb nucleotides, is
organized in three open reading frames (ORF-1 to ORF-3). An
additional ORF, ORF4, was discovered in the mNV genome in an
alternative reading frame overlapping the VP1 coding region
[10,11]. ORF1 is translated into a large polyprotein precursor
cleaved, by the viral 3C-like proteases [12–14] into six non-
structural proteins, among which the non-structural protein 7
(NS7) is endowed with RNA-dependent-RNA-polymerase (RdRp)
activity [15]. Since human cells lack RdRps, this viral class of
enzymes appears as one of the most promising targets for
development of antivirals. In our previous work, through an in sil-
ico-docking search based on a virtual library of commercially
available molecules, we identiﬁed and characterized suramin
and the analogous compound NF023 as NV-RdRp inhibitors
[16]. Since these two molecules display poor membrane
Fig. 1. Chemical structure of PPNDS.
Table 1
X-ray data-collection and reﬁnement statistics.
Protein mNV-RdRp/PPNDS
PPNDS concentration [mM] 5 mM
Space group and wavelength [Å] C2, 0.976
Unit-cell parameters (Å, ) a = 119.7, b = 197.4, c = 109.6
b = 114.1
Molecules in a.u. 3
Resolution (Å) 59.4–2.4
Mosaicity () 0.3
Unique reﬂections 90,345 (13,152)a
Completeness (%) 100 (100)
Redundancy 3.7 (3.8)
Rmerge
 (%) 14.6 (83.5)
Average I/r (I) 6.4 (2.0)
Rfactor
/Rfree§ (%) 19.2/24.9
r.m.s. bonds (Å) 0.010
r.m.s. angles () 1.39
Average protein B factors (Å2) A = 41.3, B = 43.7 C = 49.4
Average ligand B factors (Å2) A1 = 69.7, B1 = 70.0, C1 = 64.0
A2 = 73.0, B2 = 71.4, C2 = 67.3
Residues in most favored regions (%)b 93.1
Residues in additionally allowed
regions (%)b
6.7
PDB 4O4R
a Values in parentheses are for the highest resolution shell: (2.53–2.40).
b Parameters are referred to Ramachandran plot.
 Rmerge = R |I  (I)|/R I  100, where I is intensity of a reﬂection and (I) is its
average intensity.
 Rfactor = R |Fo  Fc|/R |Fo|  100.
§ Rfree is calculated on 5% randomly selected reﬂections, for cross-validation.
R. Croci et al. / FEBS Letters 588 (2014) 1720–1725 1721permeability [17–19], we focused on Pyridoxal-50-phosphate-
6-(20-naphthylazo-60-nitro-40,80-disulfonate) tetrasodium salt
(PPNDS), a different potential inhibitor identiﬁed by an in silico
search that focused on a region around the active site of hNV
RdRp. PPNDS, a speciﬁc P2X1 receptor antagonist [20], hosts a
naphthalene disulfonate head (i.e. the Suramin moiety that
strongly interacts with the enzyme [16]) and a pyridoxal phos-
phate group linked to the naphthalene head by an azo bond
(Fig. 1). In the human (h) NV-RdRp/PPNDS complex structure,
the compound was shown to bind in a region different from that
occupied by suramin or by NF023 in their respective complexes
[21]. Such a new site, named ‘‘B-site’’ in the hNV-RdRp [21], is
located in the thumb domain, more speciﬁcally in a cleft along
the exit path of the newly synthesized RNA.
Here we report the biochemical characterization, the in vitro
enzymatic inhibition activity and the 3D-structure of mNV-RdRp
in complex with PPNDS. Even though the 3D-structure showed
the inhibitor bound to the B-site, conﬁrming the relevance of this
site for the inhibition of the enzyme, mNV-RdRp binds two PPNDS
molecules; strikingly, their binding mode is reminiscent of two
stacked RNA nucleotide bases. Additional differences between hu-
man and murine NV-RdRp/PPNDS structures have been observed
and are here discussed, providing new structural bases for PPNDS
modiﬁcation aimed at improving its efﬁcacy and drug-likeness.
2. Materials and methods
2.1. Chemicals
The compound PPNDS was purchased from Santa Cruz Biotech-
nology. The compound was dissolved at 100 mM in H2O and stored
at –20 C.
2.2. Expression and puriﬁcation of the mNV-RdRp
mNV-RdRp was expressed and puriﬁed as previously described
[22]. The protein was dialyzed against 25 mM Tris/HCl pH 7.4,
1 mMDTT, 100 mMNaCl, 1 mMEDTA, and concentrated to 6 mg/ml.
2.3. mNV-RdRp inhibition assay
RdRp activity was assessed in vitro as described [16]. In brief,
we followed the synthesis of double-stranded RNA from asingle-stranded RNA polyC template (Sigma–Aldrich P4903) an-
nealed with a G12 primer (62.5 nM ﬁnal concentration) and
100 lM GTP, in a reaction mixture containing 20 mM Tris/HCl
(pH 7.5), 1 mM DTT, 25 mM NaCl, 5 mM MgCl2, 0,3 mM MnCl2, 2
U RiboLock Ribonuclease inhibitor (Life technologies), PicoGreen
Quantitation Reagent (Life technologies) (total volume of 200 ll).
Before starting the reaction, 1 ll of the protein (ﬁnal protein con-
centration of 715 nM) was incubated for 5 min with 1 ll of PPNDS
(inhibitor concentration from 0 to 10 lM). The reactions were
followed for 10 min at 30 C measuring PicoGreen ﬂuorescence
(Varian, Cary Eclipse Fluorescence Spectrophotometer). The
protein activity was evaluated subtracting the linear slope of the
ﬂuorescence from that of the assay mixture in the absence of
the enzyme. The results of three independent experiments were
averaged. Measurements of activity vs. inhibitor concentration
were used to estimate the IC50 of each inhibitor using the program
GraFit5 (Erithacus software) and reported in Fig. 1.
2.4. Biophysical characterization of the mNV-RdRp/PPNDS interaction
The ﬂuorescent dye Sypro Orange (Sigma–Aldrich) was used to
monitor protein unfolding. The unfolding process exposes hydro-
phobic regions of the protein under investigation, resulting in a
ﬂuorescence increase of the dye. Thermal shift assays of mNV-
RdRp in the absence/presence of the inhibitor were run in a
MiniOpticon Real Time PCR Detection System (Bio-Rad). Solutions
of 4 ll of the mNV-RdRp (ﬁnal protein concentration 33.6 lM)
were mixed with 3.5 ll of Sypro Orange diluted 60, 9.5 ll of its
buffer and 1 ll of PPNDS (ﬁnal concentration 50 lM). Distilled
water was added in place of the inhibitor for the control samples.
The sample plates were heated from 20 to 99 C with a heating rate
of 0.2 C/min. Fluorescence intensities were measured within
excitation/emission ranges of 470–505/540–700 nm.
2.5. Crystallization of the mNV-RdRp in presence of PPNDS
Microbatch crystallization experiments on mNV-RdRp were
assembled using an Oryx-8 crystallization robot (Douglas
Fig. 2. Protein activity vs. PPNDS concentration. Continuous lines are the ﬁts
obtained using the four parameters equation described in Section 2.
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of protein (10 mg/ml), reservoir solution and MgCl2 (25 mM in the
drop) were placed on a 96 well plate (Hampton Research), and cov-
ered by a mixture of 50% Parafﬁn oil and 50% Silicon oil. Prismatic
crystals of approximately 150  80  30 lm3 were obtained after
1 week at 20 C, in 1.6 M (NH4)2SO4, 12% glycerol, 100 mM TRIS/
HCl pH 8.4. Crystals were soaked in a cryoprotectant solution
(1.8 M (NH4)2SO4, 100 mM TRIS/HCl pH 8.4, and 25% glycerol) with
5 mM of PPNDS, in the presence of 62.5 nM dsRNA (polyC-G12) and
10 lM GTP for 36 h, then ﬂash-cooled in liquid nitrogen. Crystals
diffracted to a maximum resolution of 2.4 Å using synchrotronFig. 3. The crystal structure of mNV-RdRp bound to two molecules of PPNDS. (A) In cartoo
(low values in blue high values in red). (B) The inhibitors bound to the protein colored b
amino acids of mNV-RdRp (carbon in green sticks) interacting with PPNDS-1 (orange car
interactions between the two molecules of PPNDS (in orange) and mNV-RdRP (in greenradiation on beam-line ID23-1 at the European Synchrotron
Radiation Facility (ESRF-Grenoble, France). X-ray diffraction data
were processed using MOSFLM [23], and intensities were merged
using SCALA [24].
2.6. Structure determination and reﬁnement
The mNV-RdRp/PPNDS crystal belongs to the monoclinic space
group C2, with unit cell parameters a = 119.7 Å, b = 197.4 Å,
c = 109.6 Å; b = 114.1, with 3 molecules in the asymmetric unit
(Vm = 3.31 Å3 Da1, 62.9% solvent content [25]). The three-dimen-
sional structure was solved by Molecular Replacement (MOLREP
program) [26] using a search model based on the mNV-RdRp struc-
ture (PDB-id: 3UQS.pdb [16]). The three independent molecules in
the crystal asymmetric unit (A, B and C) were subjected to rigid-
body reﬁnement, and subsequently reﬁned using REFMAC5 [27].
A random set comprising 5% of the data was omitted from
reﬁnement for R-free calculation. Manual rebuilding and additional
reﬁnement (with BUSTER [28], REFMAC5 and COOT [29]) were
subsequently performed, as needed. Data collection, reﬁnement
statistics as well as stereochemical quality of the models are
summarized in Table 1.
3. Results
3.1. In vitro inhibition of mNV-RdRp
mNV-RdRp inhibition assays were performed monitoring the
impairment of RNA synthesis as a function of inhibitor concentra-
tion. In vitro RNA synthesis was assayed using annealed polyC-G12
and GTP as polymerase substrates, as previously described [16].
Under such experimental conditions, PPNDS inhibited mNV-RdRpn mNV-RdRp and in sticks the two PPNDS molecule colored using B-factors rainbow
y electrostatic potential (from 7 kT/e red to +7 kT/e blue; APBS, [32]. (C) The main
bon sticks) and PPNDS-2 (yellow carbon sticks). (D) Schematic representation of the
; LigPlot, [33]). Figure was created using PyMOL (http://www.pymol.org).
Fig. 4. Comparison of the binding mode of PPNDS in mNV- and hNV-RdRps and the binding of RNA to the polymerase. (A) The overall structure of mNV-RdRp (in green
cartoon) with the two PPNDS molecules (orange and yellow carbon atoms) superimposed on the hNV-RdRp/PPNDS complex, for which PPNDS (gray carbon atoms) and the C-
terminal end located into the protein active site (gray cartoon) are shown. (B) close up view as in (A) but with different orientation. (C) The overall structure of mNV-RdRp
(gray surface; with the PPNDS molecules in orange and yellow carbon atoms) superimposed on the hNV-RdRp bound to dsRNA (pdb-ID: 3BSN [31]). (D) Close up view as
in (C).
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comparable with that of Suramin (0.30 ± 0.04 lM).
3.2. Thermoﬂuorimetric assays
The speciﬁcity of the PPNDS inhibition was veriﬁed by exclud-
ing any off-target effects on the overall native protein fold, such
as ligand-induced destabilization/aggregation/denaturation. To
this aim, thermal denaturation analysis using Sypro-orange as ﬂuo-
rescent probe were performed. In fact, although the thermoﬂuori-
metric signal was markedly reduced in the presence of PPNDS,
which absorbs the incident radiation in the 470–505 nm region,
we were able to determine the mNV-RdRp melting temperature
(Tm) that resulted to be essentially the same in the absence
(Tm = 39.8 ± 0.2 C) or in the presence (Tm = 39.8 ± 0.1 C) of PPNDS
(50 lM).
3.3. Crystal structure of mNV-RdRp bound to PPNDS
Details of the PPNDS binding mode to mNV-RdRp were ad-
dressed through X-ray crystallography. To this purpose, co-crystal-
lization and soaking experiments of the puriﬁed mNV-RdRp in the
presence of saturating amounts of PPNDS were systematically set
up without signiﬁcant results. Crystals of mNV-RdRp bound to
PPNDS could be prepared only after soaking the enzyme crystals
with 5 lM of the inhibitor in the presence of dsRNA and GTP i.e.
mimicking the conditions met during the polymerase activity(see Section 2). The crystals thus obtained (belonging to the space
group C2, with 3 molecules per asymmetric unit) diffracted to
2.4 Å, maximum resolution; the mNV-RdRp/PPNDS structure was
solved by molecular replacement (model’s pdb-id: 3UQS) and re-
ﬁned to ﬁnal crystallographic R-factor/R-free values of 19.2/
24.9%, (Table 1). Inspection of difference Fourier maps at various
stages of the crystallographic reﬁnement revealed strong residual
electron density located between the thumb and palm domains,
compatible with two PPNDSmolecules that were accordingly mod-
eled in antiparallel stacking orientation (Fig. 3A–D). The inhibitor
molecule whose naphtalene disulfonate moiety is closer to the
palm domain was named PPNDS-1, the other PPNDS-2 (Fig. 3A–D).
Inspection of the enzyme/inhibitor complex structure, com-
pared to that of mNV-RdRp inhibitor-free structure (pdb-id:
3UQS [16]), shows only minor conformational changes in the pro-
tein backbone (r.m.s.d. 0.65 Å calculated over 469 C a airs). Most
speciﬁcally, we observed a slight repositioning of the 390–393 b-
turn, from Type I’ to Type II’ with ﬂipping of Leu391 W by 170
(from 36 to 130) to accommodate the 40 sulfonate and the nitro
group of PPNDS-1. Such main chain movement is accompanied by
conformational changes in the side chains of Arg392, Arg393 and
Tyr341, to accommodate both PPNDS molecules. As a whole,
PPNDS-1 shows a lower average B-factor relative to PPNDS-2,
and the two inhibitor-molecules appear to be more tightly linked
to the protein in their respective moieties that are closer to the
palm domain (Fig. 3A). In fact, PPNDS-1 naphtalene moiety is ni-
cely hosted in a low-polarity site formed by Tyr341, Met219,
1724 R. Croci et al. / FEBS Letters 588 (2014) 1720–1725Met221 and Leu391, whereas the PPNDS-2 pyridoxal phosphate
moiety, besides the stacking interaction with PPNDS-1, is H-
bonded to Tyr341 and Lys166, and its azo group is in cation–p
interaction with Arg392 (3.22 Å; Fig. 3D). Considering the inhibi-
tors’ portions that display higher mobility (as judged by B-factors),
PPNDS-2 naphtalene moiety is close to the thumb domain, with
the 40 sulphonate interacting with Ser410, Arg413, and Gln414
(belonging to the helix a13), and the PPNDS-1 pyridoxal phosphate
negative charge is balanced by Lys419.
4. Discussion
Two PPNDS molecules bind to mNV-RdRp nestled between the
palm and thumb domains, in a site close to the ‘B-site’ already char-
acterized for hNV-RdRp [21]. The two inhibitor molecules display
an evident antiparallel stacking interaction, roughly aligned along
the main alpha helices of the thumb domain (Fig. 3A), and adopt
an orientation rotated by about 60 relative to that observed for
the single PPNDS molecule bound to hNV-RdRp (Figs. 4A, B, and
S1A). Such signiﬁcant changes are likely related to the insertion of
the C-terminal segment of the hNV-RdRp (aa. 490–506) [30,31] in-
side the enzyme active site region (both in the inhibitor-free and in
the PPNDS bound structures), an event that translates into a direct
interaction of some C-terminal amino acids with the bound inhibi-
tor [21] (Fig. 4B). On the contrary, inmNV-RdRp the C-terminal seg-
ment is disordered beyond Gly488, as expected considering the
overall higher B-factors displayed by the whole C-terminal thumb
domain (Fig. 3A), thus leaving more room in the active site region
for the incoming inhibitory molecules. Interestingly, in hNV-RdRp
the C-terminal end of the protein occupies the site that in mNV-
RdRp are taken by the less mobile portions of the inhibitors, i.e. pyr-
idoxal phosphate in PPNDS-1, and naphtalene in PPNDS-2 (Fig. 4B).
It must be stressed that PPNDS-1 and PPNDS-2, in their antipar-
allel stacking interaction, are in a location close to the region that
would be taken by the newly formed ssRNA chain, as inferred by
superposition with the structure of hNV-RdRp bound to dsRNA
(pdb-id 3BSN [31]; Figs. 4C, D and S1B). In particular, PPNDS-1
and PPNDS-2, after superimposition, fall on nucleotides n-2 and
n-1, respectively (n being the nucleotide that will be linked to
the incoming NTP; Fig. 4C and D). Notably, the inhibitor portions
that are better linked to the enzyme, i.e. the naphthalene portion
of PPNDS-1 and the pyridoxal group of PPNDS-2 (Fig. 3A), would
take the place of the RNA bases, while the more mobile inhibitor
parts would match the phosphodiester backbone (Fig. 3B), in the
interaction with the ﬂexible thumb domain of the protein
(Fig. 3A). Thus, our structural results on mNV-RdRp show that
PPNDS can display properties allowing it to mimic the stacking
interaction of two linked bases in RNA as well as the phosphodies-
ter bond linkage. As a perspective, such RNA-like property of the
inhibitor might be improved by covalently linking the phosphate
moieties of the two PPNDS molecules that are found in close con-
tact in the X-ray structure here presented.
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